← Evidence map

ArticleAging2020

Retraction: miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.

Zhi-Chao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Retraction: miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling. | OpenQuestion